Monday, July 8, 2013

Sparsha Pharma looking to launch a Transdermal patch for Asthma / COPD patients

India based Sparsha Pharma is developing a transdermal patch which would need to be applied once daily and would provide relief  from various symptoms, such as dyspnea, resulting from airway obstruction in bronchial asthma, acute bronchitis, chronic bronchitis, and pulmonary emphysema. The active ingredient used in the patch would be Tulobuterol, which is a long acting β(2)-adrenergic agonist (LABA). Sparsha pharma has received a nod from the Indian drug regulators for conducting a Phase 3  trial that  would compare tulobuterol patch to salmeterol 50mcg (bid) inhaler in terms of improvement in morning peak expiratory flow (PEF) rate in patients with stable bronchial asthma and COPD

This drug delivery system ensures that the time at which the peak drug concentration in the blood is reached coincides with the morning dip in respiratory function. The use of the patch also prevents excessive increase in blood drug concentrations, thereby reducing the incidence of systemic adverse reactions. 
Tulobetrol transdermal patch is available in Japan since 1998. It is marketed under the brand name Hokunalin® Tape in Japan and was developed by by Abbott Japan and Nitton Denko Corporation.  Because the patch is easy to use and requires only once-daily application, treatment adherence of patients using the patch is good


Enter your email address:


Delivered by FeedBurner